View full meeting coverage »

Eyetube Meeting Coverage:

Retina Updates Spring 2020

 

Editorially Independent Content, Financially Supported by

Replay
Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:


Log in / Register

100-Week Data vs. 52-Week Data in PANORAMA

  Channels: Retina | Posted 5/13/2020

Jennifer Lim, MD, reviews 100-week data from the PANORAMA study, which evaluated the efficacy of aflibercept in patients with nonproliferative diabetic retinopathy. Dr. Lim compares 100-week study results with 52-week study results, delving into data on improvements in disease severity and complication rates.

aflibercept • Diabetic Retinopathy


2 / 3 Series: Retina Updates Spring 2020


These programs are not affiliated with the official program of ARVO 2020.